Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster discussion - Basic science

1591 - Patritumab (anti-HER3 antibody) augments anti-tumor immune response of adoptive transfer of autologous activated T cells for patient-derived xenograft models of breast cancer.


22 Oct 2018


Poster discussion - Basic science


Translational Research

Tumour Site

Breast Cancer


Eiji Suzuki


Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268


E. Suzuki, T. Kotake, T. Nishimura, A. Yamaguchi, F. Pu, M. Toi

Author affiliations

  • Breast Surgery, Kyoto University-Graduate school of medicine, 606-8507 - Kyoto/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1591


Signals of HER3/EGFR dimerization to PI3K/AKT/mTOR pathways are thought to be involved in cancer survival, proliferation and up-regulation of PD-L1 expression. We hypothesized that inhibition of the HER3 signal could enhance anti-tumor immunity by regulating the expression of PD-L1.


Two patient-derived xenograft (PDX) models of breast cancer were treated with patritumab (anti-HER3 antibody), polyclonal activated autologous T cells (PATCs) or a combination of patritumab and PATCs (P-PATCs). Tumor size was evaluated for anti-tumor effects of each treatment. To test immunological modulation by patritumab, tumors and liver tissue were immunohistochemically stained with anti-CD3, CD4, CD8, CD137 and PD-L1 antibody.


Although treatment of PATCs or patritumab alone showed limited anti-tumor effects, P-PATCs treatment showed a significantly greater anti-tumor response in both PDX models. Interestingly, the proportion of CD137 expressing T cell infiltration was significantly higher in P-PATCs group compared to patritumab or the PATCs group, while the proportion of CD4+ T cell infiltration was also higher in the P-PATCs group. There were equal proportions of T cells without CD137 expression presented in liver tissues in both PATCs and P-PATCs groups.


These data suggest that patritumab could contribute to augmentation of antigen-specific T cell activation leading to additional anti-tumor effects on patritumab treatment alone by means of immunological mechanisms. Thus, inhibition of HER3/neuregulin (ligand for HER3) signal might be of interesting concept for both regulation of oncologic signal and immunological modulation in HER3-expressing breast cancer.

Clinical trial identification

Legal entity responsible for the study

Eiji Suzuki.


Daiichi Sankyo Company.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.